Accelerate to discover
Related topics
Structural variants identified by Oxford Nanopore PromethION sequencing of the human genome
Aug 16, 2019
The BluePippin was used for High Pass DNA size selection prior to library construction. ONT Promethion was used for...
Fluxion Biosciences launches custom liquid biopsy NGS panel development
Aug 14, 2019
Fluxion a leading developer of precision solutions for life science research and diagnostics, announced that can...
Superior flow cytometry data with NEW Curiox Laminar Wash systems - centrifuge - less washing
Aug 12, 2019
The Laminar Wash technology provides an advantage to scientists in processing suspension cells for flow cytometry....
Next-generation cytogenetics is here
Aug 9, 2019
On ESHG 2019 conference several oral and poster presentations compared Bionano optical mapping to clinical cytogenetics...
Electroporation using Lumascope: A sustainable method for Adipogenous Mesenchymal Stem Cells
Aug 7, 2019
Human mesenchymal stem cells derived from adipose tissue (AD-hMSCs) represent a promising source for tissue engineering...
The best way to fragment DNA for genomic and paired end library construction
Aug 5, 2019
Digilab NextGen Shear DNA Shearing offers the simplest, most reproducible, and most controllable method available for...
New Cytek Full Spectrum Viewer tool, a powerful guide for your fluorochrome choices
Aug 2, 2019
Want to see which fluorochromes have unique signatures and which are identical? Then the Cytek Full Spectrum Viewer...
Software Update: Bionano releases a new pipeline for low Aalelic fraction SVs
Jul 31, 2019
Bionano Solve v3.4 is a major update that introduces an entirely new pipeline to detect SVs at low allelic fraction and...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
